Day One - Wednesday, July 31, 2024
8:00 am Check In & Coffee
8:25 am Chair’s Opening Remarks
Navigating Heart Failure Heterogeneity to Optimize Preclinical Success
8:30 am Exploring Approaches to Address the Heterogeneity of Heart Failure Through Accurate Phenotypes & Pathobiology
Synopsis
- Assessing the state of play of mechanistic drivers of variability within heart failure
- Reviewing the current classification approaches
- Assessing underlying disease pathologies linked to molecular biological mechanisms of heart failure
9:00 am Optimizing Omic Approaches Within Heart Failure
Synopsis
- Exploring omic approaches to from spatial transcriptomics to snRNA-seq to bulk RNAseq for heart failure drug development
- Assessing the state of play for heart failure patient profiling through genomics, transcriptomics, proteomics and metabolomics
- Mapping drivers for heart failure subtypes
9:30 am Speed Networking
Synopsis
A prime chance to make the most of the in-person networking with a niche community of heart failure professionals working in the space. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.
10:00 am Morning Break
10:15 am Neucardin® (rh-Neuregulin-1), A Late Stage First-in-Class Therapeutic Agent for Chronic Heart Failure
Synopsis
- A FIC biologic with novel target MoA directly on cardiomyocytes.
- Multiple trials involving over 2000 HF patients indicated a great potential to significantly reduce mortality and reverse ventricular remodeling in target patients.
- Under US/China Phase III stage and was granted FDA fast track designation, expected to be commercialized in 2025 at the earliest
10:45 am Harmonizing Omics & Heart Failure Drug Development to Create Synthesis Among Existing Knowledge mic
Synopsis
- Mastery: Explore the power of omics for a detailed understanding of genetic, protein, and metabolic factors in heart failure
- Pathway Decoding: Learn how integrated omics data unravels complex disease pathways in heart failure
- Precision Therapeutics: See how omics guides targeted drug development for effective heart failure intervention
Streamlining Human Centric iPSCs & In Vivo Preclinical Models
11:45 am One Model Does Not Fit All : The Search for Relevant Rodent Models to Feature the Different Phenogroups of HFpEF
Synopsis
- Drug development for HFpEF is partly hampered by a lack of appropriate pre-clinical models with a translational value, given the complexity of the pathophysiology of this disease and the co-existence of comorbidities in patients
- No model will capture all human HFpEF variables
- The development and the choice of a relevant model is dependent on the target phenogroup of HFpEF
12:00 pm Lunch & Networking
1:00 pm Tackling Age-Related Changes That Can Create a Permissive Environment for Heart Disease
Synopsis
- Discussing age-related gene expression signature in heart and other organs
- Assessing age-related changes in Activin signalling
- Exploring the effect of Activin on the heart
1:30 pm Optimizing HFpEF Mouse Model Development Through AAV-Renin to Increase Translatability
Synopsis
- Enhancing translational value of preclinical HFpEF model
- Utility of heart rate variability and chronic incompetence as a translationally relevant prognostic markers of heart failure in preclinical model
2:00 pm Optimizing Robust Preclinical Modelling of Heart Failure In Vivo
Synopsis
- Maximising accuracy in large animal models
- Unlocking strategies for improving biophysical techniques to account for in vivo complexities
- Integrating real world evidence into in vivo cardiac studies
2:30 pm Afternoon Break & Poster Session
Synopsis
Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversions and relationship building. Explore a range of exciting poster presentations of the latest heart failure strategies and showcase your own innovations in heart failure drug development. Don’t miss out on the chance to connect, learn, and present.
3:00 pm Roundtable Discussion | Optimal Mechanisms for Combatting Heart Failure Heterogeneity
Synopsis
A more practical and highly interactive breakout roundtable session where attendees can crowd-source solutions and share opinions on pre-assigned topic areas:
Optimal Phenotyping
What strategies can we employ to overcome the broad heart failure categorization? What characterisation approaches are most fruitful? Should differentiation be clinical, metabolic or genetic?
Back Translation
How can the back translation of large data from clinical trials with ACE inhibitors, SGLT2 inhibitors, beta blockers and GLP-1 analogs be effectively utilised to drive innovation and progression for heart failure target identification and biomarker development?
Moderators and Audience Debate Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.
Exploring the Potential of AI for HF Target Identification
3:30 pm Capitalizing on AI to Improve Ingenuity Pathways Analysis & Unlock Efficient Heart Failure Drug Screening
Synopsis
- Translating heart failure clinical trials into a dish
- Utilizing stem cell genetics and machine learning for docking analysis of heart failure drug targets
- Commutating three-dimensional structures for heart failure drug targets using machine learning
4:00 pm Leveraging Machine Learning in Target Discovery & Validation for Precision Cardiology
Synopsis
- Outlining our experience in external collaborations using machine learning methods on single-cell transcriptomics and cardiac magnetic resonance imaging
- Detailing how this has fueled our aspiration to build a robust internal platform to integrate high-throughput phenomic data
- Utilizing machine learning to drive disease understanding and uncover novel drug targets